Epstein Secrets

ons taken at committee meetings. The Supervisory Board therefore always had extensive and well-founded information on all matters of significance in the Evonik Group. At its meeting in March, the Supervisory Board focused on examining the annual financial state- ments, which had first been considered in detail by

Paragraph 5 German Stock Corporation Act/AktG), Karin Erhard (Deputy Chairwoman), Prof. Barbara Grunewald, Jurgen Neding (until September 30, 2015), Norbert Pohlmann (from Octo- ber 1, 2015), Dr. Wilfried Robers and Dr. Christian Wildmoser. • Finance and Investment Committee: Michael Radiger (Chairman), Michael V

ting, for example, from legal disputes such as claims for compensation, and from administrative proceedings and fines. In its operating busi- ness, the Evonik Group is exposed to liability risks, especially in connection with product liability, patent law, tax law, com- petition law, antitrust law and environmen

45 10 10 145 145 Dr. Werner Muller 200 200 103 103 16 13 319 316 Jurgen ituitng (until September 30, 2015)• 68 110 30 11 98 151 Norbert Pohlmann 90 90 8 6 S 104 95 Dr. Wilfried Roben 90 90 30 30 9 10 129 130 Michael ftUdiger 90 90 35 35 9 9 134 134 Ulrich Terbrack 90

PPLEMENTARY INFORMATION Independent Auditor's Report Report on the Group Management Report We have audited the accompanying management report for the Evonik Group, which is combined with the management report of the company, Evonik Industries AG, Essen, for the business year from January 1 to December 31, 201

November 3, 2015) b) Abbott Management GmbH Dr. Siegfried Luther, Glitersloh Former CFO of Bertelsmann AG a) Schaeffler AG Sparkasse Gutersloh Norbert Pohlmann, Essen Chairman of the Works Council for the Goldschmidtstrage facilities a) BKK Novitas Dr. Wilfried Robers, Gescher Chairman of the Group Exec